The activation of TLR5 on dendritic cells can promote the presentation of tumor-associated antigens to T cells, enhancing anti-tumor immunity and overcoming resistance to immune checkpoint therapy in a syngeneic breast cancer model (70). The gene discussed is TLR5; the disease is breast carcinoma.